Drug Trial Radar · NCT01688830
Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate
Last checked: Nov 20, 2026Latest source record: Jun 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
157
Actual
Start
Sep 2012
Primary completion
Nov 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 20, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective is to investigate the safety, tolerability and pharmacokinetics of BI 655075 following intravenous administration of single rising doses of BI 655075 when administered alone and after administration of dabigatran.
Conditions
- Healthy
Interventions
DabigatranDrug
BI 655075Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Drug Related Adverse Events (AE)Time frame: AEs occurring until end of follow-up (Up to 3 months after last drug administration)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
1321.1.1 Boehringer Ingelheim Investigational Site
Antwerp, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.